Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea |
Choi, Eun-Hwa
(The Committee on Infectious Diseases, the Korean Pediatric Society)
Kim, Kyung-Hyo (The Committee on Infectious Diseases, the Korean Pediatric Society) Kim, Yae-Jean (The Committee on Infectious Diseases, the Korean Pediatric Society) Kim, Jong-Hyun (The Committee on Infectious Diseases, the Korean Pediatric Society) Park, Su-Eun (The Committee on Infectious Diseases, the Korean Pediatric Society) Lee, Hoan-Jong (The Committee on Infectious Diseases, the Korean Pediatric Society) Eun, Byung-Wook (The Committee on Infectious Diseases, the Korean Pediatric Society) Jo, Dae-Sun (The Committee on Infectious Diseases, the Korean Pediatric Society) Choi, Kyong-Min (The Committee on Infectious Diseases, the Korean Pediatric Society) Hong, Young-Jin (The Committee on Infectious Diseases, the Korean Pediatric Society) |
1 | Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al. Immunogenicity of the 10-Valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) vompared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 Suppl):S66-S76. |
2 | Food and Drug Administration. Prevnar 13: clinical review of new product license application. Rockville, MD: Food and Drug Administration, 2010. |
3 | Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8. DOI ScienceOn |
4 | Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59:258-61. |
5 | Nuorti JP, Whitney CG;Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children-Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 2010;59(RR-11):1-18. |
6 | The Korean Pediatric Society. Pneumococcal vaccine. In: Lee HJ, editor. Immunization Guideline. 6th ed. Seoul: The Korean Pediatric Society, 2008;196-216. |
7 | Dagan R, Jacobs MR, Greenberg D. Pneumococcal infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan S, editors. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: WB Saunders, 2004;1204-58. |
8 | Lee JH, Cho HK, Kim KH, Kim CH, Kim DS, Kim KN, et al. Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): A retrospective multicenter study. J Korean Med Sci 2011;26:174-83. DOI ScienceOn |
9 | Kim SH, Song EK, Lee JH, Kim NH, Lee JA, Choi EH, et al. Changes of serotype distribution of Streptococcus pneumoniae isolated from children in Korea over a 15 year-period (1991-2005). Korean J Pediatr Infect Dis 2006;13:89-98. |
10 | Lee TJ, Chun JK, Choi KM, Yong DE, Lee KW, Kim DS. Trends in serotype distribution of clinical isolates of Streptococcus pneumoniae : a single center experience from 2001 to 2006. Korean J Pediatr Infect Dis 2006;13:115-23. |
11 | Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee HJ, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81. DOI |
12 | Korean Centers for Disease Control and Prevention. Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae clinical isolates in Korea. Public Health Wkly Rep 2010;3:1-7. |
13 | World Health Organization. Technical Report Series, No. 927, Annex 2. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, 2009. |
![]() |